PISANI, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 3.892
EU - Europa 3.197
AS - Asia 555
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 4
AF - Africa 1
Totale 7.659
Nazione #
US - Stati Uniti d'America 3.884
IE - Irlanda 957
SE - Svezia 741
CN - Cina 510
UA - Ucraina 391
IT - Italia 319
DE - Germania 293
FI - Finlandia 186
GB - Regno Unito 105
FR - Francia 81
PL - Polonia 38
IN - India 26
BE - Belgio 24
AT - Austria 19
RU - Federazione Russa 15
NL - Olanda 12
IR - Iran 9
CH - Svizzera 5
CA - Canada 4
ES - Italia 4
TR - Turchia 4
AU - Australia 3
CZ - Repubblica Ceca 3
EU - Europa 3
JP - Giappone 3
MX - Messico 3
NZ - Nuova Zelanda 3
BR - Brasile 2
CL - Cile 2
VN - Vietnam 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CR - Costa Rica 1
DK - Danimarca 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
ID - Indonesia 1
RO - Romania 1
Totale 7.659
Città #
Dublin 956
Jacksonville 828
Chandler 699
Nyköping 321
Beijing 232
Dearborn 193
Princeton 189
Cambridge 179
Ashburn 146
Des Moines 146
Medford 125
Ann Arbor 116
Boardman 96
New York 50
Woodbridge 47
Wilmington 46
San Mateo 40
Shenyang 40
Warsaw 37
Jinan 35
Messina 31
Nanjing 27
Brussels 23
Bremen 22
Pune 22
Houston 21
Seattle 21
Hebei 20
Vienna 19
Tianjin 18
Norwalk 16
Rome 16
Ningbo 15
Zhengzhou 15
Jiaxing 14
Milan 14
Lancaster 13
Haikou 12
Fuzhou 11
Hangzhou 11
Naples 11
Ardabil 9
Washington 9
Taizhou 8
Helsinki 7
Nanchang 7
Augusta 6
Taiyuan 6
Amsterdam 5
Auburn Hills 5
Caserta 5
Clearwater 5
Guangzhou 5
Leawood 5
Verona 5
Catania 4
Changsha 4
Faenza 4
Kunming 4
Pozzo Di Gotto 4
Saint Petersburg 4
Turin 4
Bari 3
Bronte 3
Izmir 3
Kemerovo 3
Lanzhou 3
London 3
Los Angeles 3
Melito di Napoli 3
Monza 3
Mumbai 3
Redwood City 3
Riva 3
San Giuliano 3
Stezzano 3
Acerra 2
Alessandria 2
Atlanta 2
Berlin 2
Catanzaro 2
Cedar Knolls 2
Chiampo 2
Dong Ket 2
East Los Angeles 2
Edinburgh 2
Elk Grove Village 2
Foggia 2
Hefei 2
Kriens 2
Latina 2
Lodi 2
Manfredonia 2
Massa Fiscaglia 2
Mexico City 2
Monmouth Junction 2
Montecchio 2
Napoli 2
San Giovanni Bianco 2
Strasbourg 2
Totale 5.098
Nome #
" Stato confusionale di probabile natura iatrogena"; " Verosimile screzio psicotico"; " Sindrome Cefalalgica"; " Disturbo d'Ansia". Varie ipotesi ed una sola diagnosi: SENC 188
Rischio di iperomocisteinemia in pazienti con Epilessia, portatori del diplotipo C677T/A1298C della MTHFR 118
Distribuzione di due polimorfismi genici della MTHFR in pazienti con Epilessia e correlazione con i livelli serici di omocisteina 100
FORCED NORMALISATION: OBSERVATION WITH NEW ANTIEPILEPTIC DRUGS 80
ALLOPURINOL AS ADD-ON THERAPY IN REFRACTORY EPILEPSY - A DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY 70
beneficial effect of donezepil in a malnourished surgical patient with severe nonalcoholic wernicke's encephalopathy 70
Effetto della viloxazina sui livelli ematici di oxcarbazepina e dei relativi metaboliti 69
FORCED NORMALISATION: A RETROSPECTIVE ANALYSIS OF RISK FACTORS 68
Carbamazepine-viloxazine interaction in patients with epilepsy 67
THE EFFECT OF COMBINING VIGABATRIN AND TIAGABINE, TWO DRUGS WITH COMPLEMENTARY GABAERGIC MECHANISMS, AGAINST NMDA-INDUCED EXCITOTOXICITY 66
Neuroprotective effects of levetiracetam against kainic acid toxicity are mediated by inhibition of lipid peroxidation 65
Aspetti neuropsichiatrici dell'epilessia 65
Antiepileptic drugs and MTHFR Polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients 64
"Valproic acid-amitriptyline interaction in man 64
Effect of viloxazine on serum carbamazepine levels in epileptic patients 63
Hyperhomocysteinemia and retinal vascular changes in patients with epilepsy. 62
A sensitive gas chromatograpic assay for the determination of serum viloxazine concetration using a nitrogen-phosphorus selective detector". Ther. Drug Monit., 6:484-488, 1984. 62
An epidemiological study of the clinical impact of pharmacokinetic anticonvulsant drug interactions based on serum drug level analysis 62
Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs. 62
CARBAMAZEPINE VALNOCTAMIDE INTERACTION IN EPILEPTIC PATIENTS - IN-VITRO IN-VIVO CORRELATION 61
Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia 61
Il concetto di normalizzazione forzata in epilettologia 61
Prime esperienze su efficacia e tollerabilità della tiagabina in pazienti con epilessia farmacoresistente 61
Antidepressant drugs and seizure susceptibility: From in vitro data to clinical practice 60
Ruolo dei farmaci antiepilettici nella neuroprotezione da ischemia cerebrale 60
Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. 60
Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study 60
The effect of lamotrigine on peripheral nerves. 58
Hyperhomocysteinemia in patients with epilepsy: does it play a role in the pathogenesis of brain atrophy? A preliminary report. 58
Effect of valpromide on the pharmacokinetics of Carbamazepine-10,11-epoxide 57
Is retinal assessment useful in epileptic patients with hyperhomocysteinemia? 57
A study on the metabolism of dipropylacetamide to dipropylacetic acid in rats 57
Controllo totale di crisi con l’associazione lamotrigina-gabapentin in un caso di epilessia sintomatica. 56
Effects of psychotropic drugs on seizure threshold 55
Meccanismi eccitotossici in un modello sperimentale in vitro: effetti della lamotrigina sul rilascio di amminoacidi eccitatori 55
Dipropylacetic acid plasma levels; diurnal fluctuations during chronic treatment with dipropylacetamide 54
Single-dose kinetics of primidone in acute viral hepatitis 54
Objective cognitive dysfunction assessment in patients with subjective cognitive complaints: does it allow an early differentiation between demnetia and pseudo-dementia? 54
INFLUENCE OF COMEDICATION ON THE METABOLISM OF VALPROATE 53
Differential interactions of valproic acid and valpromide with Carbamazepine in man 53
Lamotrigina ed effetti elettrofisiologici sul sistema nervoso periferico. 51
Pharmacokinetics and therapeutic plasma monitoring of antiepileptic drugs 51
Evaluation of Tricyclic Antidepressant Plasma Levels by an Automated Enzyme Immunoassay (EMIT) in Comparison to a High-Performance Liquid Chromatographic Method 51
ATTENTION CHARACTERIZATION IN PATIENTS WITH FRONTAL AND TEMPORAL LOBE EPILEPSY 51
EFFECTS OF THE ANTIDEPRESSANT DRUG VILOXAZINE ON OXCARBAZEPINE AND ITS HYDROXYLATED METABOLITES IN PATIENTS WITH EPILEPSY 50
THE INFLUENCE OF ELECTROENCEPHALOGRAPHIC FOCUS LATERALITY ON EFFICACY OF CARBAMAZEPINE IN COMPLEX PARTIAL AND SECONDARILY GENERALIZED TONIC-CLONIC SEIZURES 50
ELEVATION OF PLASMA PHENYTOIN BY VILOXAZINE IN EPILEPTIC PATIENTS - A CLINICALLY SIGNIFICANT DRUG-INTERACTION 50
Lamotrigina ed effetti elettrofisiologici sul sistema nervoso periferico 50
CLINICALLY RELEVANT ANTI-EPILEPTIC DRUG-INTERACTIONS 49
Diurnal fluctuations in plasma drug levels:studies with valproic acid and carbamazepine 49
The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction 48
Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment 48
Repetitive transcranial magnetic stimulation induced slow wave activity modification: A possible role in disorder of consciousness differential diagnosis? 48
Specific Patient Features Affect Antiepileptic Drug Therapy Decisions: Focus on Gender, Age, and Psychiatric Comorbidities 48
Liquid chromatographic assay of lamotrigine,a new antiepileptic drug, by a hig-speed column 47
VIGABATRIN-INDUCED DECREASE IN SERUM PHENYTOIN CONCENTRATION DOES NOT INVOLVE A CHANGE IN PHENYTOIN BIOAVAILABILITY 47
INTERACTION OF LAMOTRIGINE WITH SODIUM VALPROATE 47
Accidents in patients with epilepsy: types, circumstances, and complications: a European cohort study 47
Distribution of attention in normal people as a function of spatial location: Right-left, up-down 47
Attivita' parossistica ed agenti farmacologici: attivazione ed inibizione 47
Limited place for plasma monitoring of new antiepileptic drugs in clinicalpractice. 46
The 894G > T (Glu298Asp) variant in the endothelial NOSgene and MTHFR polymorphisms influence homocysteine levels in patients withcognitive decline. 46
Neuroprotective effect of remacemide hydrochloride against NMDA-induced excitotoxicity in isolated chick embryo retina 45
Valproic acid fails to displace phenobarbitone and carbamazepine from plasma protein binding sites in epileptic patients 45
CONTRIBUTION OF INTERICTAL BRAIN PERFUSION SPECT IN ASSESSING PATIENTS WITH EPILEPSY 45
Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy 45
Antidepressant effect of vagal nerve stimulation in epilepsy patients: a systematic review 45
Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients 44
Effects of remacemide and lamotrigine on MNDA-induced excitotoxicity in isolated chick embryo retina 44
Le terapie associative in epilettologia 44
LIQUID-CHROMATOGRAPHIC ANALYSIS OF ANTIEPILEPTIC DRUGS - AN OVERVIEW 44
Identification of amoebae in the CSF in a patient with meningoencephalitis. 44
Neuroprotective effects of lamotrigine and remacemide on excitotoxicity induced by glutamate agonists in isolated chick retina 44
Valproic acid-ethosuximide interaction: A pharmacokinetic study 44
Sodium valproate and valpromide:Differential interactions with carbamazepine in epileptic patients 44
Clinical and pharmacokinetic study of conventional carbamazepine vs a new controlled-release (CR) formulation: a double-blind, cross-over trial 44
Coenzyme Q10, Hyperhomocysteinemia and MTHFR C677T polymorphism in Levodopa-treated Parkinson’s disease patients 44
Differential distribution of epilepsy in patients with different types of dementia: a single-centre, retrospective study 44
LAMOTRIGINE IN RESISTANT CHILDHOOD EPILEPSY 43
Morbidity in patients with epilepsy: type and complications: a European cohort study 43
SOCIAL ASPECTS OF EPILEPSY IN THE ADULT IN SEVEN EUROPEAN COUNTRIES 43
Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration 43
Increased dipropylacetic acid bioavailability from dipropylacetamide by food 43
Crisi epilettiche indotte dall’assunzione di leflunamide in pazienti in terapia con carbamazepina 43
Il significato del monitoraggio dei farmaci nella compliance 43
Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study 42
Levetiracetam protects against kainic acid-induced toxicity 42
Phenylethylmalonamide in essential tremor.A double-blind controlled study 42
Non-convulsive status epilepticus after ischemic stroke: a hospital-based stroke cohort study 42
Risk factors for unprovoked epileptic seizures in multiple sclerosis: a systematic review and meta-analysis 42
Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? Insights from in vitro studies 41
The importance of drug interactions in epilepsy therapy 41
Ipsilesional attentional-approach neglect or crossover effect 41
COULD LAMOTRIGINE BE USEFUL IN STATUS EPILEPTICUS - A CASE- REPORT 41
Pharmacokinetics of a valproic acid isomer, valnoctamide, in healthy subjects 41
Antiepileptic drug comedications in clinical practice 41
Prevenzione dell’epilettogenesi: revisione della letteratura, raccomandazioni terapeutiche, proposte di ricerca 41
Normalizzazione forzata e fattori di rischio: un'analisi retrospettiva 40
Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine 40
Disturbi del linguaggio e farmaci antiepilettici: analisi prospettica dei possibili fattori di rischio 40
Totale 5.365
Categoria #
all - tutte 25.748
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.748


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201931 0 0 0 0 0 0 0 0 0 7 17 7
2019/20201.395 206 88 7 84 18 189 207 143 28 154 247 24
2020/20211.012 149 7 205 56 39 165 16 105 16 101 91 62
2021/20221.118 19 167 23 42 22 3 66 55 25 152 194 350
2022/20232.741 235 172 96 214 257 257 29 182 1.156 17 80 46
2023/2024542 68 122 60 69 46 130 15 26 2 4 0 0
Totale 7.747